Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
UCB Pharma
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients having completed study C87042 \[NCT00308581\] (previously treated with infliximab)
You may not be if
Subject withdraw from C87042 \[NCT00308581\] study
Subject who received treatment other than certolizumab pegol and other than medications permitted in C87042 \[NCT00308581\] study
Subjects from countries where certolizumab pegol is authorized in Crohn's disease treatment
Female patients of childbearing age who are NOT practicing (in the Investigator's opinion) effective birth control. All female patients must test negative on a serum pregnancy test before study entry and negative on urine testing immediately before every certolizumab pegol administration
